Track record · closed signal

Novo Nordisk A/S ADR (NVO) — closed signal from July 1, 2025

Partial Published before the outcome was known, scored automatically when the window closed on September 29, 2025 — -18.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$68.25 Published $80.99 Target $55.50 Window close $71.00 Peak
$65.51 – $67.47Entry zone — fair-value band
$68.25Published — price the day we called it
$80.99Target — the price the thesis aimed for
$71.00Peak — highest point inside the window, not a realized return
$55.50Window close — end-of-window price, context only

What happened

Partial

Reached 20% of the predicted growth at its peak, without hitting the target.

At window close
-18.7%
realized, from the publication price to the last close inside the window
Peak gain
+4%
peak, from the publication price — not a realized return
S&P 500, same window
+7.8%
SPY over the identical days, dividend-adjusted
Window close
$55.50
last close inside the window, ended September 29, 2025
Peak price
$71.00
peak on July 25, 2025 — not a realized return
Days to target
—

The thesis — published July 1, 2025

Predicted growth
+20%
over the measurement window
Target price
$80.99
the price the thesis aimed for
Entry zone
$65.51 – $67.47
the fair-value band we waited for
Price at publication
$68.25
published July 1, 2025
Confidence
82%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

The share price fell 15% after some launch problems with Wegovy, yet demand for its weight-loss drugs is up 50%. Extra factory space in Q3 and key study results in late August could both lift the stock soon. Shares now sit near their long-term average price, and because the setback was about shipping, not customer interest, a move back to $83-$86 within three months looks realistic.

Primary drivers

  • Prescriptions for its GLP-1 drugs are up over 50% despite early launch bumps.
  • Extra production lines coming in Q3 should ease Wegovy supply shortages.
  • Late-August study results for CagriSema could act as a spark for the stock.
  • Charts show the share looks beaten down, setting up for a possible rebound.

How it played out

NVO: target was not reached

Lyra published NVO on 2025-07-01 at $68.25 with expected growth of 20%. The thesis pointed to a 15% share-price fall after Wegovy launch problems, demand for weight-loss drugs up 50%, extra factory space in Q3, and late-August CagriSema study results. It expected a move back to $83-$86 within three months.

Inside the window from 2025-07-01 to 2025-09-29, NVO peaked at $71 on 2025-07-25, a 4% gain. It stayed below the $80.99 target and never reached it. The stock ended at $55.50. The thesis missed.

What happened during the window

On 2025-07-29, Novo Nordisk lowered its 2025 sales growth outlook to 8%-14% and operating profit growth outlook to 10%-16%. On 2025-09-10, it announced 9,000 job cuts, about 11% of its workforce.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals